重症疾病中的微生物组
该综述检索PubMed和OVID至2025年8月的英文文献,聚焦微生物组与重症医学干预及器官结局的关系。人体存在眼、皮肤、口咽、肺、膀胱和胃肠道的多种独特微生物组,其中胃肠道微生物组在健康维持及危重患者生理恢复或衰竭中起关键作用。ICU患者因入院疾病及抢救/管理治疗常出现微生物平衡破坏;理解疾病和治疗驱动的微生物组变化及其影响,可能揭示改善重症结局的策略。结论建议ICU医生掌握微生物组评估基础、疾病与治疗药物引起的适应或适应不良改变,以及当前和新兴的减轻病理微生物组、恢复稳态的干预措施。
要点
- 人体存在眼、皮肤、口咽、肺、膀胱和胃肠道的多种独特微生物组,胃肠道微生物组是常驻微生物生命周期之外最具可识别活性的部分。
- 胃肠道微生物组在健康维持及危重或损伤患者的生理恢复或衰竭中起关键作用。
- ICU患者因入院疾病过程及抢救或管理治疗,微生物平衡破坏常见。
- 理解疾病调控和治疗驱动的微生物组变化及其影响,可能揭示改善重症监护结局的策略。
- ICU医生将从理解微生物组评估基础、疾病与治疗药物引起的适应或适应不良改变、以及减轻病理微生物组诱导和恢复稳态的当前与新兴干预中获益。
适用人群与场景
- 危重或损伤患者(综述讨论重症监护中微生物组的管理影响)
- ICU患者
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 综述检索PubMed和OVID至2025年8月的英文文献,排除灰色文献;人体存在眼、皮肤、口咽、肺、膀胱和胃肠道的多种独特微生物组,胃肠道微生物组在健康维持及危重或损伤患者生理恢复或衰竭中起关键作用,ICU患者因入院疾病及抢救或管理治疗常出现微生物平衡破坏。
证据类型、等级与局限
- 综述(叙述性综述),证据等级原文未提及;局限:检索限于PubMed和OVID至2025年8月的英文文献,排除灰色文献,未提供系统评价或荟萃分析方法。
对床旁实践的改变
- 提示ICU医生应理解微生物组评估基础、疾病与治疗药物引起的适应或适应不良改变,以及减轻病理微生物组诱导和恢复稳态的当前与新兴干预;原文未给出具体可改变的操作、药物剂量或适用/不适用人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To review how the human microbiome impacts management of the critically ill or injured patient.
DATA SOURCES: English-language manuscripts were sourced from PubMed and OVID from inception to August 2025.
STUDY SELECTION: Manuscripts addressing the mammalian microbiome, microbiome characterization, microbiome derangement, microbiome restoration, critical care interventions, the ICU, and organ system outcomes related to the human microbiome. Gray literature was excluded.
DATA EXTRACTION: Data that informed microbiome characterization, derangement, support, manipulation, as well as the impact of the microbiome on critical care medicine interventions or outcomes were abstracted.
DATA SYNTHESIS: Humans demonstrate a variety of unique microbiomes spanning eyes, skin, oropharynx, lung, bladder, and gastrointestinal tract. The most identifiable active outside of the lifecycles of resident microbiota is the gastrointestinal microbiome. The gastrointestinal microbiome plays a critical role in health maintenance as well as the physiologic recovery-or failure-of the critically ill or injured. Microbial balance disruption is common in ICU patients due to index admission disease processes as well as rescue or management therapeutics. Understanding how disease-modulated and therapy-driven microbiome changes occur-as well as their impact-may reveal strategies to improve critical care outcomes. The gastrointestinal microbiome serves as a lens through which microbial actions and host-microbe-regulated functions may be understood.
CONCLUSIONS: Based on the impact of the human microbiome on critical care-relevant interventions and outcomes, the ICU clinician will benefit from understanding: 1) microbiome evaluation fundamentals, 2) microbiome adaptive or maladaptive alteration by disease process as well as therapeutic agents, and 3) current and emerging interventions to mitigate pathobiome induction and restore homeostasis to improve outcomes.
参考来源
- Klingensmith NJ, Leonard JM, Martinez-Quinones P, et al. The Microbiome in Critical Illness. Crit Care Med. 2026. PMID: 42644690. doi:10.1097/CCM.0000000000007327
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。